drug development
-
The patient is the point: The changing landscape innovation in drug development
Bringing in market access and collaboration earlier in the process, viewing reimbursement as the last leg of the drug developmental journey, and collaborating across key functions are practices we can evolve so that as many patients as possible can reap the rewards that are waiting for them.
-
MedCity Influencers, BioPharma
Discovering biomarkers to find new ways to treat diseases of unmet need
Blending computational biology and AI-based methods, the goal is to identify new targets, pair these with effective chemistry, and define biomarkers to optimally position novel therapies.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
MedCity Influencers, BioPharma
Drug R&D is broken; how to put the tech in biotech
We need to embrace principles from the tech industry and incorporate lessons learned from the pandemic to address the challenges of R&D productivity in pharma.
-
MedCity Influencers, BioPharma
What have we learned about accelerating drug development from Covid-19?
This pandemic has shown that collaboration, biosimulation and decentralized trials, and active preparedness programs lead to fast, effective drug development when we really need it.
-
Bristol Myers Squibb SVP Ho Sung Cho highlights legacy and ongoing research in protein degradation
Cho discusses Bristol Myers Squibb’s research efforts in the field of protein degradation to advance potential treatments for a broad range of diseases. In a recent MedCity Pivot Podcast, he also shared insights on his approach to drug discovery, perspectives on dealing with failure, and some of the work his teams are doing in the COVID-19 space.
-
One year after founding, startup EQRx raises $500M to advance goal of cheaper cancer drugs
The latest funding brings total investment in the company to $750 million. The money has gone, in part, toward licensing of promising drug candidates in breast, lung and other cancers.
-
BioPharma, Artificial Intelligence
Immunai joins 10x Genomics program to boost drug development
Together, the two companies say can give drugmakers a better view at the cellular level of how a patient’s immune system is responding to a cerain therapy.
-
Startups, Artificial Intelligence, BioPharma
Immunai decloaks with $20M in seed funding to map immune system with machine learning
The company, led by an ex-Palantir engineer and a former Harvard postdoctoral researcher, has developed machine learning algorithms to identify nuances in cells, mechanisms of action and biomarkers that could aid immunotherapy and cell therapy development.
-
Medicare Advantage startup Clover Health launches drug development arm
The company has signed an initial partnership with Genentech that will focus on understanding the genetic components that are related to a person’s risk of developing ocular diseases like macular degeneration.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Focus on specialty drugs reflects ‘cyclical nature’ of biopharma, industry veteran says
Adam Schechter, an adviser to Merck’s CEO, said at the Veeva Summit Tuesday that many primary care diseases – such as cardiovascular disease and Alzheimer’s – still have significant unmet needs.
-
Artificial Intelligence, BioPharma
Watson for Drug Discovery may be down, but AI in biopharma isn’t out
Last month, it was reported that IBM would stop selling Watson for Drug Discovery, but executives in the field of biopharma artificial intelligence say the field is still going strong.
-
Nearly three-quarters of late-stage pipeline drugs come from emerging biopharma, report finds
The report, from IQVIA, stated that growth in the number of registration studies with active controls indicates payers’ increasing interest in comparative-effectiveness data.
-
Artificial Intelligence, BioPharma
AI drug development partnership between GlaxoSmithKline, Exscientia yields first drug candidate
The in vivo molecule was discovered under a two-year-old partnership between the two companies to discovery drugs using artificial intelligence. It will be developed for COPD.
-
Scripps Research explores new model to advance drug development, sustainability
Nonprofit research institutes have faced a tough financial road, but Scripps research is exploring a new model for drug development.
-
Do biopharma companies take the right approach with cancer patients?
Biopharma companies need to start conversations with patients as early as in Phase I during the drug development process and, most importantly, maintain a feedback loop with patients throughout the whole development process.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
